Efficacy and safety of apixaban compared with warfarin at different levels of INR control for stroke prevention in atrial fibrillation.

Slides:

Advertisements

Similar presentations

ROCKET-AF Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial.

Advertisements

JOURNAL REVIEW Newer Antithrombotics in AF 1 Dr Ranjith MP Senior Resident Department of Cardiology Government Medical college Kozhikode.

אפיקסבאן למניעת stroke ודימום בחולי פרפור עליות פרופ ' דורון זגר מנהל יחידת הביניים / ט. נ. לב, מ. מ. מנהל המערך הקרדיולוגי, מרכז רפואי סורוקה הפקולטה.

Apixaban versus Aspirin in Atrial Fibrillation Patients ≥ 75 years old: An Analysis from the AVERROES Trial Kuan H Ng, Olga O Shestakovska, John W. Eikelboom,

PROTECT-AF (LAA Closure with Watchman vs Warfarin in AF and Stroke) A long-term (45-month) follow-up analysis of device therapy with Watchman vs warfarin.

Efficacy and Safety of Dabigatran vs. Warfarin in Patients with Atrial Fibrillation - Japanese population in the RE-LY ® - Shinya Goto, MD., PhD. Tokai.

ARISTOTLE TRIAL Dr R Nyabadza GPST1 Ward 32. Structure AF, stroke and CHA 2 -DS 2 VASC Anticoagulant choices ARISTOTLE trial Cost NICE guidance and the.

ARISTOTLE TTR Subanalysis

Study by: Granger et al. NEJM, September 2011,Vol No. 11 Presented by: Amelia Crawford PA-S2 Apixaban versus Warfarin in Patients with Atrial Fibrillation.

Atrial Fibrillation Stroke Prevention with Oral Anticoagulants Why is there discordance between guideline committees & specialists when the data is based.

AF and NOACs An UPDATE JULY 2014

Randomized Evaluation of Long- term anticoagulant therapY Dabigatran Compared to Warfarin in 18,113 Patients with Atrial Fibrillation at Risk of Stroke.

ROCKET AF Renal Dysfunction Substudy Objective Evaluate the 2950 patients in the per-protocol cohort with a baseline CrCl of 30 to 49 mL/min who received.

The Long Term Multi-Center Extension of Dabigatran Treatment in Patients with Atrial Fibrillation (RELY-ABLE) study To reviewers and moderators: These.

Antiplatelet or Anticoagulant: Do They Have the same Efficacy? University of Central Florida Deborah Andrews RN, BSN.

UK/CVS (1) | February 2013 Emerging technologies for stroke prevention in atrial fibrillation UK/CVS (1) | Date of preparation: February 2013.

Guillaume Pare MD Genetic determinants of dabigatran plasma levels and their relation to bleeding On behalf of RE-LY Genetics: Guillaume Pare MD, Niclas.

Stroke Prevention Using the Oral Direct Thrombin Inhibitor Ximelagatran in Patients With Nonvalvular Atrial Fibrillation SPORTIF V Trial Presented at American.

ARISTOTLE Objectives Primary: test for noninferiority of apixaban, a novel oral direct factor Xa inhibitor, versus warfarin Secondary: test for superiority.

S. Goto1, J. Zhu2, L. Lisheng2, BH. Oh3, D. Wojdyla4, M. Hanna5, J. Horowitz6, L. Wallentin7, D. Xavier8, JH. Alexander4 (1) Tokai University School of.

Presented by Renato D. Lopes, MD, PhD, Duke Clinical Research Institute, Duke University, USA for the ARISTOTLE investigators. Efficacy and Safety of Apixaban.

Shinya Goto,1 Jun Zhu,2 Liu Lisheng,2 Byung-Hee Oh,3 Daniel M. Wojdyla,4 Michael Hanna,5 John D. Horowitz,6 Lars Wallentin,7 Denis Xavier,8 John H. Alexander4.

Case study - patient presenting with newly diagnosed NVAF with prior CAD Full Prescribing Information is provided at the end of this presentation EUAPI581k;

Is there a future role for warfarin in stroke prevention for NVAF in 2014 EUAPI581f, April 2014 Full Prescribing Information is provided at the end of.

Gli anticoagulanti diretti nel mondo reale

N Engl J Med 2009;361: Stuart J. Connolly, M.D., Michael D. Ezekowitz, M.B., Ch.B., D.Phil., Salim Yusuf, F.R.C.P.C., D.Phil., John Eikelboom,

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation Manesh R. Patel, M.D., Kenneth W. Mahaffey, M.D., Jyotsna Garg, M.S., Guohua Pan, Ph.D.,

The Management of AF Warfarin New anticoagulants 16 Sept 2011.

Manesh R. Patel, M.D., Kenneth W. Mahaffey, M.D., Jyotsna Garg, M.S., Guohua Pan, Ph.D., Daniel E. Singer, M.D., Werner Hacke, M.D., Ph.D., Gunter Breithardt,

Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation NEJM Aug 27, 2015.

Review on NOACs Studies DR. KOUROSH SADEGHI TEHRAN UNIVERSITY OF MEDICAL SCIENCES.

1 Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation R3 Dae Ho Kim / Prof. Jin Bae Kim N Engl J Med 2011; DOI: Manesh R. Patel, M.D.,

Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart DiseaseClinical Perspective by Michael D. Ezekowitz, Rangadham.

The Efficacy of Dabigatran versus Warfarin for Stroke Prevention in Patients With Atrial Fibrillation: Systematic Review Karim Bouferrache Pacific University.

Digoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter? Renato D. Lopes, MD,

Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Non-valvular Atrial Fibrillation.

Figure 2 Survival curves in the elderly vs. younger patients

CRT 2017: Putting LAA closure in the age of DOACs into perspective

Addressing the Challenges in Primary and Secondary Stroke Prevention

David R. Holmes, Jr., M.D. Mayo Clinic, Rochester

A Comparison of RE-LY and ROCKET AF Trial Designs and Outcomes

Figure 1 Flow chart diagram of high-risk group AF patients

Efficacy and Safety of Dabigatran vs

Anticoagulation in Atrial Fibrillation

Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.

Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: Time for a reappraisal Gregory.

Anticoagulant Safety Remains a Problem Emergency Hospitalizations for Adverse Drug Events.

RE-CIRCUIT Trial design: Patients with atrial fibrillation undergoing catheter ablation were randomized to uninterrupted dabigatran 150 mg twice daily.

Randomized Evaluation of Long-term anticoagulant therapY

Oral Anticoagulation and Preventing Stent Thrombosis

US Guidelines US Guidelines Low-risk Patients.

Barriers to Oral Anticoagulant Use for Stroke Prevention in AF

Access to NOAC Therapy:

Digoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter? Renato D. Lopes, MD,

NOAC Use in AF: REAL-WORLD Studies WITH REAL RESULTS

Applying Real-World Evidence in Atrial Fibrillation Into Clinical Care:

Access to NOAC Therapy:

Dabigatran vs Warfarin in Patients with Atrial Fibrillation – Results

Major Gastrointestinal Bleeding Often Is Caused by Occult Malignancy in Patients Receiving Warfarin or Dabigatran to Prevent Stroke and Systemic Embolism.

Atrial Fibrillation.

Influence of Renal Function on the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Non–Vitamin K Antagonist Oral Anticoagulants Matthew R.

Anticoagulation and Thrombosis Management

Assessing Atrial Fibrillation: Real-World Data vs Clinical Trials

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

ACC 2003 Late Breaking Trials

5 Good Minutes on Atrial Fibrillation-related Stroke

(p for noninferiority = 0.01)

Gianluigi Savarese et al. JCHF 2016;4:

by Renato D. Lopes, Patrícia O. Guimarães, Bradley J. Kolls, Daniel M

The CHA(2)DS2-(VASc) stroke risk and HAS-BLED bleeding risk index are calculated by totalling the scores for each risk factor present.68–71 The lower graph.

Presentation transcript:

Efficacy and safety of apixaban compared with warfarin at different levels of INR control for stroke prevention in atrial fibrillation

ARISTOTLE trial: Apixaban versus warfarin in patients with atrial fibrillation Main results C. Granger. Hot Line 1. ESC, Paris 2011

Efficacy and safety of Apixaban compared with Warfarin at different levels of INR Control for stroke Prevention in Atrial Fibrillation Lars Wallentin. ESC, Paris 2011 ARISTOTLE pre-specified analysis Conclusion: the benefits of apixaban over warfarin in preventing stroke, reducing bleeding and improving survival appear consistent regardless of center’s quality of INR control

CONCLUSION -In patients with atrial fibrillation, apixaban is superior to warfarin at preventing stroke or systemic embolism, causes less bleeding, and results in lower mortality. -The benefits of apixaban over warfarin in preventing stroke, reducing bleeding and improving survival appear consistent regardless of centers’quality of INR control. -Therefore, in patients with atrial fibrillation, apixaban is a more effective and safer treatment than warfarin across a wide range of warfarin management.